表抗心律失常治疗对猝死一级预防的研究汇总 Trials Therapy Study Size(F-U duration! All-cause mortality Population CAST I Encainide/ n=1455(300days) 7,7%w3.0%(PL)p<0.001 Post-MI lowered LVEF complex VEA cAsT‖ n =1325(18 months) Early SD: 17 VS 3(PL)p<0.02 Post-MI LVEF <40% SWORD d-Sotalol n=3121(18 months) 50%31%(PLp<0.01 Post-MI LVEF≤40% EMIATAmiodarone n=1486(21 months) 13.9%Vs 13.7%(PL)=NSPost-MI LVEF<40% CAMIAT Amiodarone n=1202(1.79 years I 6.2% VS 8.3%(PL)p=NS Post-MI complex VEA GESICA Amiodarone n=516(24 months 33.5% Vs 41.4%(control) p<0.3 CHF LVEF $35% STAT-CHFI Amiodarone n=674(45 months) 39%s42%(PL)p=NS CHF10 VPCs/hour MADIT Implantable n=196(27 months) 15%vs 38%(control) p=0.009 Post-MI LVEF <% defibrillator NSVT Inducible. non- suppressible VT CABG Implantable n=900(32 months) 22.6%vs 20.9%(control) p=NS Coronary bypass Patch trial defibrillator surgery patients LVEF ≤35% Abnormal SA ECG 级预防以药物为主,IcD?Trials Therapy Study Size (F-U duration) All-cause mortality Population CAST I CAST II SWORD EMIAT CAMIAT GESICA STAT-CHF MADIT CABG Patch trial n=1455 (300 days) n=1325 (18 months) n=3121 (18 months) n=1486 (21 months) n=1202 (1.79 years) n=516 (24 months) n=674 (45 months) n=196 (27 months) n=900 (32 months) Post-MI lowered LVEF complex VEA Post-MI LVEF≤40％ Post-MI LVEF≤40％ Post-MI LVEF≤40％ Post-MI complex VEA CHF LVEF ≤35% CHF10 VPCs/hour Post-MI LVEF ≤35% NSVT Inducible, non￾suppressible VT Coronary bypass surgery patients LVEF ≤35% Abnormal SA￾ECG Encainide/ Flecainide Moricizine d-Sotalol Amiodarone Amiodarone Amiodarone Amiodarone Implantable defibrillator Implantable defibrillator 7.7% vs 3.0% (PL) p<0.001 Early SD: 17 vs 3 (PL) p<0.02 5.0% vs 3.1% (PL) p<0.01 13.9% vs 13.7% (PL) p=NS 6.2% vs 8.3% (PL) p=NS 33.5% vs 41.4% (control) p<0.3 39% vs 42% (PL) p=NS 15% vs 38% (control) p=0.009 22.6% vs 20.9% (control) p=NS 表II 抗心律失常治疗对猝死一级预防的研究汇总 一级预防以药物为主，ICD？